The goal of this a single arm prospective study is to evaluating the 3-month return of urinary continence outcomes of patients undergoing the transvesical retzius sparing robotic radical prostatectomy (TRS-RALP) for standard of care surgical prostate removal for treatment of prostate cancer. The main question it aims: To have patients respond to questionnaires to collect exploratory data on patient's quality of life (QoL; EuroQol-5 Dimension 5-Level \[EQ-5D-5L\] and prostate cancer related urinary, bowel, and sexual function questionnaires (Expanded Prostate cancer Index Composite for Clinical Practice (EPIC-CP), at their standard of care perioperative visits at baseline and at 4 weeks, 3- and 6-months post operatively.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
EQ-5D-5L #1.1
Timeframe: Pperioperative baseline
EQ-5D-5L #1.2
Timeframe: 4 weeks postoperatively
EQ-5D-5L #1.3
Timeframe: 3 months postoperatively
EQ-5D-5L #1.4
Timeframe: 6 months postoperatively
EPIC-CP #2.1
Timeframe: perioperative baseline
Expanded Prostate cancer Index Composite for Clinical Practice (EPIC-CP) #2.2
Timeframe: 4 weeks postoperatively
Expanded Prostate cancer Index Composite for Clinical Practice (EPIC-CP) #2.3
Timeframe: 3 months postoperatively
Expanded Prostate cancer Index Composite for Clinical Practice (EPIC-CP) #2.4
Timeframe: 6 months postoperatively